Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
23 Giugno 2023 - 11:00PM
(NASDAQ: ENOB). Enochian BioSciences Inc., a
company developing gene-modified cell immunotherapies for cancer
and infectious diseases, wishes to advise that its 2023 Annual
Stockholder Meeting (the “Annual Meeting”), which was scheduled to
be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was
convened and adjourned, without any business being conducted, due
to the lack of the required quorum.
As a result of the required quorum not being present, the Annual
Meeting has been adjourned to 12:00 p.m. (Eastern Time) on Friday
July 21, 2023 (“Adjourned Annual Meeting”) to allow additional time
for the Company’s stockholders to vote on the proposals set forth
in the Company’s definitive proxy statement filed with the United
States Securities and Exchange Commission (“SEC”) on May 15, 2023,
and thereby satisfy the required quorum for the meeting. The
Adjourned Annual Meeting will be conducted via a live webcast. To
register to attend the virtual Annual Meeting, please visit
http://www.viewproxy.com/enochianbio/2023/htype.asp before 11:59 PM
EST on July 20, 2023.
During the current adjournment period, the Company will continue
to solicit votes from its stockholders with respect to the
proposals set forth in the Company’s proxy statement. The Company
has engaged a proxy solicitor, Alliance Advisors LLC, to assist
management with obtaining adequate votes to achieve the required
quorum of at least a majority of the outstanding shares of common
stock.
Only stockholders of record as of the record date, May 10, 2023,
are entitled to vote. Valid proxies previously submitted in respect
of the Annual Meeting will be voted at the Adjourned Annual Meeting
unless properly revoked, and stockholders who have previously
submitted a valid proxy card or otherwise voted need not take any
action unless they wish to change their vote.
The Company encourages all stockholders of record as of May 10,
2023 who have not yet voted, to do so.
Stockholders who have any questions or require any assistance
with how to complete a proxy or who do not have the required
materials, may contact Alliance Advisors at (866) 612-8937 or email
virtualmeeting@viewproxy.com.
Important Information
This material may be deemed to be solicitation material in
respect of the Adjourned Annual Meeting to be held on July 21,
2023. In connection with the Annual Meeting, the Company filed a
definitive proxy statement with the SEC on May 15, 2023. BEFORE
MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE
DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED
WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE
ADJOURNED MEETING. The definitive proxy statement has been mailed
to stockholders who are entitled to vote at the Annual Meeting. No
changes have been made to the proposals to be voted on by
stockholders at the Annual Meeting. The proxy statement and 2022
Annual Report on Form 10-K are available at
http://www.viewproxy.com/enochianbio/2023.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this press release include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational, and financial goals. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward-looking statement contained in
this press release is subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statement, including as set forth in Enochian
BioSciences’ most recent Annual Report on Form 10-K filed with the
SEC. Investors should not place considerable reliance on the
forward-looking statements contained in this press release.
Investors are encouraged to read our publicly available filings for
a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this release, and we undertake no obligation to update
or revise any of these statements.
Source: Enochian BioSciences Inc.
FOR FURTHER INFORMATION:
Contact: ir@enochianbio.com
Grafico Azioni Enochian Biosciences (NASDAQ:ENOB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Enochian Biosciences (NASDAQ:ENOB)
Storico
Da Dic 2023 a Dic 2024